Trospium chloride | 曲司氯胺 | Trospium (chloride) | mAChR Inhibitor

首页 / 抑制剂/激动剂 / 神经信号通路 / AChR / Trospium chloride

曲司氯铵 /Trospium chloride {[allProObj[0].p_purity_real_show]}

货号：A293957 同义名： 曲司氯胺 / Trospium (chloride);Relaspium

Trospium chloride是一种竞争性拮抗剂，作用于毒蕈碱型胆碱受体，用于治疗膀胱过度活跃的症状。

Trospium chloride 化学结构
CAS号：10405-02-4

Trospium chloride 3D分子结构
CAS号：10405-02-4

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Trospium chloride 纯度/质量文件产品仅供科研

货号：A293957 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • JMC, 2024. Ambeed. [ A919389 , A918471 , A995972 ]; • Anal. Chem., 2024, 96(50): 19947-19954. Ambeed. [ A261947 , A1165388 ]; • ACS Biomater. Sci. Eng., 2024. Ambeed. [ A220462 ]; • ACS Biomater. Sci. Eng., 2024. Ambeed. [ A165235 , A110205 ]; • Pharmaceutics, 2024, 16(12): 1546. Ambeed. [ A272538 , A187261 , A691302 , A506702 ]; 更多 >

AChR 亚型比较

产品名称	AChE ↓ ↑	AChR ↓ ↑	mAChR ↓ ↑	nAChR ↓ ↑	其他靶点	纯度
Donepezil	+++ hAChE, IC50: 11.6 nM bAChE, IC50: 8.12 nM					98%
Loganin	++ AChE, IC50: 3.95 μM					99%+
topride HCl	++ AChE, IC50: 2.04 μM					98%
Dehydroevodiamine HCl	✔					99%+
Jatrorrhizine	++ AChE, IC50: 872 nM					99%+
Palmatine	++ AChE, IC50: 0.51 μM					98%
(-)-Huperzine A	++++ AChE (G4 form), Ki: 7 nM					98%
Galanthamine HBr	++ AChE, IC50: 0.35 μM					98%
Trospium chloride		✔				99%
Tiotropium Bromide Monohydrate		✔				98+%
Gallamine Triethiodide		+ AChR, IC50: 68.0 μM				98%
Hexamethonium Bromide		✔				99%
Pancuronium dibromide		✔				98%
Neostigmine bromide		✔				98%
Orphenadrine citrate		✔				98%
Oxybutynin		✔				98%
Irsogladine		✔			PDE	99%
Pyridostigmine bromide		✔				99+%
Rivastigmine		+ AChR, IC50: 5.5 μM				98%
Paroxetine hydrochloride		✔				99%
Rocuronium Bromide		✔				98%
Tropicamide			+++ M4 mAChR, IC50: 8 nM			98%
Diphenmanil methylsulfate			✔			99%
Umeclidinium bromide			✔			95%
Otilonium bromide			✔			98%
Flavoxate HCl			+ mAChR, IC50: 12.2 μM			99%
Ipratropium bromide			✔			98%
Diphenidol HCl			✔			98%
Darifenacin hydrobromide			++++ M3 mAChR, pKi: 8.9			98%
Aclidinium Bromide			++++ M2 mAChR, Ki: 0.1 nM M4 mAChR, Ki: 0.21 nM			98%
Oxybutynin chloride			✔			99%
Pentoxyverine citrate			✔			98%
Solifenacin			✔			98%
Catharanthine				✔		98%
Benzethonium chloride				+++ α7 nAChRs, IC50: 122 nM α4β2 nAChRs, IC50: 49 nM		99+%
Vinblastine sulfate				+ nAChR, IC50: 8.9 μM		99%
PNU-120596				++ α7 nAChR, EC50: 216 nM		99+%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Trospium chloride 生物活性

靶点

AChR

描述

Trospium Chloride is antagonist of acetylcholine muscarinic receptors and the cornerstone of pharmacotherapy for the symptoms of overactive bladder (OAB). Trospium chloride, dosed 20 mg twice daily, is significantly superior to placebo in improving cystometric parameters, reducing urinary frequency, reducing incontinence episodes, and increasing urine volume per micturition^[3]. Moreover, trospium chloride (1 mg/kg, intravenously) permeation across the BBB (blood-brain barrier ) is not increased in ageing perse, and therefore, the occurrence of adverse CNS (central nervous system) drug effects is also not expected to increase with ageing^[4].

Trospium chloride 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02386072	-		Completed	-	-
NCT00547378	Urinary Incontinence, Urgency-... 展开 >>frequency Overactive Bladder 收起 <<	Phase 4	Completed	-	-
NCT01499069	Overactive Bladder	Not Applicable	Unknown	December 2015	Korea, Republic of ... 展开 >> Samsung Medical Center Recruiting Seoul, Korea, Republic of, 135-710 Contact: Kyu-Sung Lee, Ph.D 82-2-3410-3554 ksleedr@skku.edu Contact: Bong-Hee Lim, BA 82-2-3410-3743 bonghee.lim@sbri.co.kr Sub-Investigator: Deok Hyun Han, PhD Sub-Investigator: Young-Suk Lee, PhD Sub-Investigator: Ha Na Lee, PhD 收起 <<

Trospium chloride 参考文献

[1]Staskin DR. Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladder. Urol Clin North Am. 2006 Nov;33(4):465-73, viii.

[2]Doroshyenko O, Jetter A, et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet. 2005;44(7):701-20.

[3]Guay DR. Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Ther Clin Risk Manag. 2005 Jun;1(2):157-67. doi: 10.2147/tcrm.1.2.157.62912. PMID: 18360555; PMCID: PMC1661617.

[4]Kranz J, Petzinger E, Geyer J. Brain penetration of the OAB drug trospium chloride is not increased in aged mice. World J Urol. 2013 Feb;31(1):219-24. doi: 10.1007/s00345-011-0803-z. Epub 2011 Nov 27. PMID: 22120415; PMCID: PMC3557395.

Trospium chloride 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.34mL

0.47mL

0.23mL

11.68mL

2.34mL

1.17mL

23.37mL

4.67mL

2.34mL

Trospium chloride 技术信息

CAS号	10405-02-4
分子式	C₂₅H₃₀ClNO₃
分子量	427.964

别名	曲司氯胺 ;Trospium (chloride);Relaspium
运输	蓝冰

存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Inert atmosphere,2-8°C

溶解方案

细胞实验：

DMSO: 35 mg/mL(81.78 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H₂O: 100 mg/mL(233.66 mM)

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

配制的工作液建议现用现配，短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02386072	-		Completed	-	-
NCT00547378	Urinary Incontinence, Urgency-... 展开 >>frequency Overactive Bladder 收起 <<	Phase 4	Completed	-	-
NCT01499069	Overactive Bladder	Not Applicable	Unknown	December 2015	Korea, Republic of ... 展开 >> Samsung Medical Center Recruiting Seoul, Korea, Republic of, 135-710 Contact: Kyu-Sung Lee, Ph.D 82-2-3410-3554 ksleedr@skku.edu Contact: Bong-Hee Lim, BA 82-2-3410-3743 bonghee.lim@sbri.co.kr Sub-Investigator: Deok Hyun Han, PhD Sub-Investigator: Young-Suk Lee, PhD Sub-Investigator: Ha Na Lee, PhD 收起 <<
NCT00547378	-		Completed	-	-
NCT03602508	-		Active, not recruiting	February 2019	Australia ... 展开 >> Site AU10000 Sydney, Australia Korea, Republic of Site KR82001 Seoul, Korea, Republic of 收起 <<
NCT01166438	Urge Urinary Incontinence ... 展开 >> Overactive Bladder 收起 <<	Phase 3	Completed	-	United States, Alabama ... 展开 >> The University of Alabama at Birmingham Birmingham, Alabama, United States, 35249 United States, California USCD Medical Center La Jolla, California, United States, 92037 Kaiser Permanente San Diego, California, United States, 92037 United States, Illinois Loyola University Medical Center Maywood, Illinois, United States, 60153 United States, Michigan Oakwood Hospital Dearborn, Michigan, United States, 48124 Beaumont Hospital Royal Oak, Michigan, United States, 48073 United States, North Carolina Duke University Durham, North Carolina, United States, 27710 United States, Ohio Cleveland Clinic Cleveland, Ohio, United States, 44195 United States, Pennsylvania Magee-Women's Hospital Pittsburgh, Pennsylvania, United States, 15213 United States, Texas University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390 United States, Utah University of Utah Salt Lake City, Utah, United States, 84132 收起 <<
NCT00800462	Spinal Cord Injury ... 展开 >> Neurogenic Detrusor Overactivity 收起 <<	Phase 4	Completed	-	Canada, Manitoba ... 展开 >> University of Manitoba, Health Sciences Centre Winnipeg, Manitoba, Canada, R3A1R9 Canada, Ontario Toronto Rehabilitation Institute, Lyndhurst Centre Toronto, Ontario, Canada, M4G 3V9 收起 <<
NCT01166438	-		Completed	-	-
NCT03697252	Schizophrenia	Phase 2	Recruiting	November 5, 2019	United States, Arkansas ... 展开 >> Woodland International Research Group, LLC Recruiting Little Rock, Arkansas, United States, 72211 United States, California Synergy East Recruiting Lemon Grove, California, United States, 91945 Collaborative Neuroscience Network, LLC. Recruiting Long Beach, California, United States, 90806 NRC Research Institute Recruiting Orange, California, United States, 92868 Artemis Institute for Clinical Research Recruiting San Diego, California, United States, 92103 United States, Georgia Atlanta Center for Medical Research Recruiting Atlanta, Georgia, United States, 30331 United States, Maryland CBH Health, LLC Recruiting Gaithersburg, Maryland, United States, 20877 United States, New Jersey Hassman Research Institute Recruiting Berlin, New Jersey, United States, 08009 United States, Ohio Midwest Clinical Research Center (and IP Shipment) Recruiting Dayton, Ohio, United States, 45417 United States, Texas Community Clinical Research, Inc. Recruiting Austin, Texas, United States, 78754 InSite Clinical Research, LLC Recruiting DeSoto, Texas, United States, 75115 Pillar Clinical Research, LLC Recruiting Richardson, Texas, United States, 75080 收起 <<
NCT03109379	Idiopathic Overactive Bladder ... 展开 >>With Urinary Incontinence 收起 <<	Phase 1	Active, not recruiting	June 30, 2018	United States, Michigan ... 展开 >> William Beaumont Hospital - Royal Oak Royal Oak, Michigan, United States, 48073 Michigan Institute of Urology Troy, Michigan, United States, 48084 United States, New York Accumed Research Garden City, New York, United States, 11530-1664 United States, Virginia Urology of Virginia Virginia Beach, Virginia, United States, 23462 收起 <<
NCT03572231	-		Recruiting	December 2019	Korea, Republic of ... 展开 >> Site KR410008 Recruiting Daejeon, Korea, Republic of Site KR410009 Recruiting Incheon, Korea, Republic of Site KR410001 Recruiting Seoul, Korea, Republic of Site KR410003 Recruiting Seoul, Korea, Republic of Site KR410006 Recruiting Seoul, Korea, Republic of Taiwan Site TW158001 Recruiting Hualien City, Taiwan 收起 <<
NCT00465959	Chronic Obstructive Pulmonary ... 展开 >>Disease 收起 <<	Phase 1 Phase 2	Completed	-	United States, South Carolina ... 展开 >> United States Investigational Site Spartanburg, South Carolina, United States 收起 <<
NCT00801684	Chronic Obstructive Pulmonary ... 展开 >>Disease (COPD) 收起 <<	Phase 2	Completed	-	United States, South Carolina ... 展开 >> Spartanburg Medical Research Spartanburg, South Carolina, United States, 29303 收起 <<
NCT03011463	Pharmacokinetics ... 展开 >> Inhibition Enzyme Drug Interaction Potentiation 收起 <<	Phase 1	Completed	-	-
NCT03168828	Neurogenic Detrusor Overactivi... 展开 >>ty 收起 <<	Phase 1	Active, not recruiting	September 30, 2018	United States, Michigan ... 展开 >> Michigan Institute of Urology Troy, Michigan, United States, 48084 United States, North Carolina Carolinas HealthCare System Charlotte, North Carolina, United States, 28207 United States, Virginia Urology of Virginia Virginia Beach, Virginia, United States, 23462 United States, Washington Virginia Mason Seattle, Washington, United States, 98101 收起 <<
NCT00801684	-		Completed	-	-
NCT01922115	Mental Competency ... 展开 >> Urinary Bladder, Overactive Cognitive Function 收起 <<	Phase 4	Completed	-	United States, North Carolina ... 展开 >> Unc Chapel Hill Urogynecology A2 Clinic Chapel Hill, North Carolina, United States, 27517 收起 <<
NCT01178827	-		Completed	-	-
NCT01922115	-		Completed	-	-
NCT01178827	Overactive Bladder	Phase 4	Completed	-	United States, Utah ... 展开 >> Salt Lake City, Utah, United States 收起 <<
NCT01089751	Overactive Bladder	Phase 4	Completed	-	United States, California ... 展开 >> La Mesa, California, United States 收起 <<
NCT03104101	Overactive Bladder	Not Applicable	Completed	-	-
NCT00932022	Obesity Overa... 展开 >>ctive Bladder Incontinence 收起 <<	Phase 4	Completed	-	United States, California ... 展开 >> La Mesa, California, United States 收起 <<
NCT00932022	-		Completed	-	-
NCT01089751	-		Completed	-	-
NCT00986401	Healthy	Phase 1	Completed	-	United States, Arizona ... 展开 >> Tempe, Arizona, United States 收起 <<
NCT00863551	Elderly Pharm... 展开 >>acokinetics Overactive Bladder 收起 <<	Phase 4	Completed	-	United States, California ... 展开 >> Glendale, California, United States 收起 <<
NCT00863551	-		Completed	-	-
NCT03709992	Ureter Stone ... 展开 >>Quality of Life Ureter Obstruction 收起 <<	Not Applicable	Not yet recruiting	November 1, 2019	-
NCT02831231	Schizophrenia	Phase 1	Completed	-	United States, Ohio ... 展开 >> Medpace Cincinnati, Ohio, United States, 45227 收起 <<
NCT00986401	-		Completed	-	-

曲司氯铵 /Trospium chloride {[allProObj[0].p_purity_real_show]}

Trospium chloride 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Trospium chloride 质控信息

Trospium chloride 生物活性

Trospium chloride 临床研究

Trospium chloride 参考文献

Trospium chloride 实验方案

Trospium chloride 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

曲司氯铵 /Trospium chloride {[allProObj[0].p_purity_real_show]}

Trospium chloride 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Trospium chloride 质控信息

Trospium chloride 生物活性

Trospium chloride 临床研究

Trospium chloride 参考文献

Trospium chloride 实验方案

Trospium chloride 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Trospium chloride 纯度/质量文件产品仅供科研